Research
Hormonal
In randomized controlled trials, GLP-1RAs induce a weight reduction of 4.36 kg compared to placebo.
GLP-1RAs can be beneficial for weight loss in a controlled setting post-bariatric surgery.
StrongSupportsmedium confidence
Data from RCTs showed that the use of GLP-1RAs induced weight reduction of 4.36 kg compared to placebo.
Why this rating
Based on a systematic review and meta-analysis of 17 studies.
Source
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment
Caroline K. Kramer et al. · The Journal of Clinical Endocrinology & Metabolism · 2024
DOI 10.1210/clinem/dgae176
Meta-analysisCited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →